about
FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathwaysSynovial sarcoma: recent discoveries as a roadmap to new avenues for therapyNuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics.Current management of pediatric soft tissue sarcomas.β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition.Anti-cancer drug 3,3'-diindolylmethane activates Wnt4 signaling to enhance gastric cancer cell stemness and tumorigenesis.Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.Surgical outcomes following resection for sporadic abdominal wall fibromatosis.The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.Transforming growth factor-β1 signaling promotes epithelial-mesenchymal transition-like phenomena, cell motility, and cell invasion in synovial sarcoma cells.Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma.The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors.Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.Deregulated angiogenesis in chronic lung diseases: a possible role for lung mesenchymal progenitor cells (2017 Grover Conference Series).Casein kinase1α activators, a precision weapon for CRC.ATR Is a Therapeutic Target in Synovial Sarcoma.The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.Casein kinase 1α: biological mechanisms and theranostic potential.Soft Tissue Sarcoma Cancer Stem Cells: An Overview
P2860
Q28076296-19B3099D-6E75-4825-9849-4295210CBFF7Q28087134-4F88B23B-42AE-4AA6-A256-FB58600EEE27Q33676352-A64888B4-BF5F-4147-A4F9-F617893E560DQ36262280-36D4FAE6-D1B3-4BC5-A383-CFDFB9484FA5Q36356064-F002FBEA-0BAC-45D7-BA19-488DA058E14AQ37086018-BE3EC57D-732F-4259-90A9-94E2100DCD24Q37150456-43F1A6DE-5CAD-4902-8AA7-5BB3861F625AQ38194092-77D30F98-BE30-4C04-97B8-E5A8D45D4C66Q38608775-5D7E0D03-2E77-48CF-8024-EB605D873E4FQ38614137-3F4583F2-5743-44F9-BCFF-803264748345Q38760598-A01EB2FE-C8FD-4ECF-AF11-247D8B11130EQ38796815-3721DB5C-6825-4FF3-A252-6FFAC7631C85Q39036272-7E63549B-1871-47B2-9485-BF1D57AD9080Q39233440-50928AF3-5F02-4AF0-B160-971F73F18340Q39396803-42FC5D5A-6322-4A7C-8AF6-3A78B548486EQ47110433-9EDB61F3-6C5E-4810-9747-C721777D39D5Q47117383-B4688C14-9CAE-4B6B-8136-16EF1FF805B1Q47149025-48499C5C-D6B9-4A14-B152-08E1A817AE3AQ47643551-777E862B-AB45-49EA-8166-ABA1C2D344F1Q50420957-8A0FAACD-5F3E-4884-B509-9087B75B35D6Q54940982-C8352120-D994-4869-BCD4-6D334DCC555FQ58707604-D3AFA9B2-C91C-4CA1-BE74-5F22CDBA6591
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting the Wnt pathway in synovial sarcoma models.
@en
Targeting the Wnt pathway in synovial sarcoma models.
@nl
type
label
Targeting the Wnt pathway in synovial sarcoma models.
@en
Targeting the Wnt pathway in synovial sarcoma models.
@nl
prefLabel
Targeting the Wnt pathway in synovial sarcoma models.
@en
Targeting the Wnt pathway in synovial sarcoma models.
@nl
P2093
P2860
P1433
P1476
Targeting the Wnt pathway in synovial sarcoma models
@en
P2093
Andrea L Frump
Barbara Fingleton
Christina B Garcia
Darren Orton
Fiona Yull
Josiane E Eid
Linda Gleaves
Mario R Capecchi
Michael N VanSaun
P2860
P304
P356
10.1158/2159-8290.CD-13-0138
P577
2013-08-06T00:00:00Z